drugset / Trial / NCT05384821

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

NCT05384821

Phase 1/2 Recruiting 28 enrolled Centre Oscar Lambret
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.

Timeline

Start
2022-09-14
Primary completion
2028-05
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule Oral
Subject Irinotecan Small molecule Oral
Subject Isotretinoin Other / unclassified Oral
Subject Temozolomide Small molecule Oral
Subject Vincristine Small molecule Intravenous

Indications